Compare · ISPC vs MEDP
ISPC vs MEDP
Side-by-side comparison of iSpecimen Inc. (ISPC) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ISPC and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $18.29B, about 5132.9x ISPC ($3.6M).
- Both names hit the wire about 7 times in the past 4 weeks.
- MEDP has more recent analyst coverage (25 ratings vs 2 for ISPC).
- Company
- iSpecimen Inc.
- Medpace Holdings Inc.
- Price
- -
- -
- Market cap
- $3.6M
- $18.29B
- 1M return
- -36.93%
- -
- 1Y return
- -97.43%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2016
- News (4w)
- 7
- 7
- Recent ratings
- 2
- 25
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest ISPC
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Regulation FD Disclosure, Financial Statements and Exhibits
- iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products
- iSpecimen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form PRE 14A filed by iSpecimen Inc.
- iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent
- SEC Form DEFR14A filed by iSpecimen Inc.
- SEC Form PRER14A filed by iSpecimen Inc.
- SEC Form 8-K filed by iSpecimen Inc.
- iSpecimen Supports Hospital Validation of New Chemistry Analyzer
Latest MEDP
- SEC Form SCHEDULE 13G filed by Medpace Holdings Inc.
- General Counsel & Corp. Secy. Ewald Stephen P sold $859,050 worth of shares (1,245 units at $690.00), decreasing direct ownership by 6% to 19,098 units (SEC Form 4)
- Exec. VP, Operations Burwig Susan E sold $13,540,000 worth of shares (20,000 units at $677.00) (SEC Form 4)
- SEC Form 4 filed by Medpace Holdings Inc.
- SEC Form 10-Q filed by Medpace Holdings Inc.
- SEC Form 8-K filed by Medpace Holdings Inc.
- Medpace Holdings, Inc. Reports Third Quarter 2026 Results
- SEC Form 4 filed by Medpace Holdings Inc.
- SEC Form 4 filed by Medpace Holdings Inc.
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.23% to 12,303 units (SEC Form 4)